The presentation of the eagerly awaited IMPROVE-IT trial, scheduled for Monday at the American Heart Association meeting, won’t be accompanied by a simultaneous publication in the New England Journal of Medicine. Although no one except for a small group of insiders knows for sure, this news may have important implications. … Click here to read the full post on Forbes. …
IMPROVE-IT Trial Paper Won’t Be Published Right Away In The New England Journal Of Medicine
November 13, 2014 by 1 Comment
Colchicine Found Effective in Acute Pericarditis
September 12, 2013 by Leave a Comment
Although colchicine has been shown to be beneficial in patients with recurrent pericarditis, which is thought to have a large inflammatory component related to an immune response, until now its efficacy in a first episode of acute pericarditis has been uncertain, as these episodes are thought to usually have a viral component that might benefit from…
Some Patients With Minor Stroke Or TIA May Benefit From Early Clopidogrel And Aspirin
June 26, 2013 by Leave a Comment
Some people with minor ischemic stroke or transit ischemic attack (TIA) may benefit from dual antiplatelet therapy with aspirin and clopidogrel, according to a large new study from China published in the New England Journal of Medicine. In the immediate period following a TIA or minor stroke people are at high risk for having a major stroke. Aspirin…
Large NIH Trial Finds No Cardiovascular Benefits For Weight Loss And Exercise In Type 2 Diabetics
June 24, 2013 by 1 Comment
A large NIH-sponsored trial has found that an intensive lifestyle intervention was no better than standard care in reducing cardiovascular events in people with type 2 diabetes. The results of the Look AHEAD trial were presented today at the American Diabetes Association meeting and published simultaneously in the New England Journal of Medicine. 5,145 people with type 2 diabetes were randomized…
Recent Comments